GoodCell

GoodCell (“LifeVault Bio”), the company decoding human health to extend and improve the quality of life through technology powered by science, today announced it has filed a patent that will extend its intellectual property (IP) for quantifying risk and assessing cell quality to identify and validate indicators of COVID-19 morbidity and mortality. The filing marks a critical step toward a test to identify patients at risk of COVID-19 complications, which could aid public health officials’ decisions for developing safe reopening strategies and identifying the most vulnerable groups.
Source:
businessware
June 16, 2020
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

The contents of our site should not be construed as legal, tax or financial advice nor its contents be distributed, published or reproduced in whole or in part, or be relied upon as the basis for any investment. It is the responsibility of any person(s) in possession of the information contained in this site to inform themselves of, and to observe, the legal requirements also applying to the countries of their respective citizenship, residence or domicile. We make no representations as to its accuracy whatsoever and offer no undertakings. The content of our site is for general information only. Our site does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorized or would be unlawful to make such offer or solicitation or if it is unlawful without compliance with additional registration or filing requirements. The contents of our site are not available in the United States and should not be accessed by any US person.